Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk.

Slides:

Advertisements

Similar presentations

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Advertisements

Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.

Increasingly, women who are asymptomatic present in pregnancy with a known thrombophilia, typically detected because of screening following identification.

Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.

Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”

Chapter Ten Venous Disease Coalition Hypercoagulability VTE Toolkit.

Understanding the scientific literature (Reading and evaluation of a research paper) Prof David Lane Department of Haematology Hammersmith Hospital Campus.

Thrombophilia National Haemophilia Director

Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis by Marcello Di Nisio, Anne W. S. Rutjes, Noemi.

Deficiencies of Proteins C, S and Antithrombin and Activated Protein C Resistance – Their Involvement in the Occurrence of Arterial Thromboses Report PGY.

Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses by Klaus Juul, Anne Tybjærg-Hansen, Rolf Steffensen, Steen Kofoed, Gorm Jensen, and.

Changes in Body Weight After Total Hip Arthroplasty: Short-term and Long-term Effects by Nienke Paans, Martin Stevens, Robert Wagenmakers, Jan van Beveren,

Inge M. van Schouwenburg

Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.

Arterioscler Thromb Vasc Biol

by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M

Discounted Coagulation Profiles Clinical Laboratories.

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

by Nadine Martel, James Lee, and Philip S. Wells

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Ida Martinelli, Anthonie W. A. Lensing, Saskia.

Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study by.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Catheter-related deep venous thrombosis in children with hemophilia

Pregnancy outcomes after maternal exposure to rituximab

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first.

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Rapid Simultaneous Screening of Factor V Leiden and G20210A Prothrombin Variant by Multiplex Polymerase Chain Reaction on Whole Blood by Encarnación Gómez,

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Primary testicular lymphoma

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

An Unknown Genetic Defect Increases Venous Thrombosis Risk, through Interaction with Protein C Deficiency Sandra J. Hasstedt, Edwin G. Bovill, Peter.

Latest lymphoma classification is skin deep

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Stavros V. Konstantinides et al. JACC 2016;67:

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL by Christian H. Geisler, Mars.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

Inherited thrombophilia Screening

AZA treatment induces a distinct gene-expression pattern in stromal cells. AZA treatment induces a distinct gene-expression pattern in stromal cells. (A-C)

by Wendy Lim, Sara K. Vesely, and James N. George

sIgM levels or signaling and FISH lesions in CLL

Graft flow as a predictor of thrombosis in hemodialysis grafts

Impact of age on clinical risk scores in follicular lymphoma

Rituximab immunotherapy: it’s getting personal

Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S by Michael Makris, Michael Leach,

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Myeloproliferative neoplasms and thrombosis

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia by Leslie Skeith, Marc Carrier, Risto Kaaja,

Nephrotic syndrome is a prothrombotic state of variable magnitude.

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Cold agglutinin disease

Presentation transcript:

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives by Willem M. Lijfering, Jan-Leendert P. Brouwer, Nic J. G. M. Veeger, Ivan Bank, Michiel Coppens, Saskia Middeldorp, Karly Hamulyák, Martin H. Prins, Harry R. Büller, and Jan van der Meer Blood Volume 113(21):5314-5322 May 21, 2009 ©2009 by American Society of Hematology

Flow diagram of the family cohort Flow diagram of the family cohort. * indicates probands were classified according to their index defect. Flow diagram of the family cohort. * indicates probands were classified according to their index defect. In case of multiple defects, the index defect was chosen in the following order: antithrombin deficiency, protein C deficiency, protein S deficiency, FV Leiden, prothrombin 20210G>A, high factor VIII levels, and hyperhomocysteinemia. Willem M. Lijfering et al. Blood 2009;113:5314-5322 ©2009 by American Society of Hematology

Event-free survival of first venous thrombosis in relatives with thrombophilic defects. * indicates that when analyzing idiopathic events, provoked events were censored and vice versa. Event-free survival of first venous thrombosis in relatives with thrombophilic defects. * indicates that when analyzing idiopathic events, provoked events were censored and vice versa. Willem M. Lijfering et al. Blood 2009;113:5314-5322 ©2009 by American Society of Hematology

Risk of first venous thrombosis associated with cosegregation. Willem M. Lijfering et al. Blood 2009;113:5314-5322 ©2009 by American Society of Hematology

Event-free survival of recurrent venous thrombosis in relatives of probands with thrombophilic defects. Event-free survival of recurrent venous thrombosis in relatives of probands with thrombophilic defects. Willem M. Lijfering et al. Blood 2009;113:5314-5322 ©2009 by American Society of Hematology